Pharmsville팜스빌

Pharmsville's revenue has fallen sharply since 2021 and it still posts operating losses, though it carries little debt.

Trailing revenue to H1 2026 was ₩11.2B, down from ₩39.0B in 2021, and operating income was a loss of ₩0.69B. Net income of ₩3.0B is far above operating income, but the data does not explain the gap. The shares closed at ₩3,390, within a 52-week range of ₩3,135 to ₩4,320.

What stands out

• Revenue fell 23.9% in 2025 to ₩12.7B, extending a multi-year decline from ₩26.1B in 2022 and ₩21.4B in 2023.
• Operating margin has been negative in 2024, 2025 and the trailing period, after a 15.8% margin in 2021.
• Net income (₩3.0B trailing) is well above operating income, but the data does not say which items drove it, so it may not reflect core operations.
• Balance sheet looks light: cash of ₩4.9B against borrowings of ₩9.4M, with liabilities at 2.5% of equity.
• The company's own profile names it Farmsbill, while its listed English name is Pharmsville; the profile text also says it sells through several overseas markets, but the data gives no overseas revenue split.

What to watch

• Amended half-year and Q1 2026 reports were filed on 20 August 2026; the data does not say what changed.
• Whether revenue stabilises and operating losses narrow in the next reported period, given the 2026 trend.
• The Serbian export and distribution agreement for Wilac D001, announced 22 October 2026; the data gives no sales size for it.